Ginwa Enterprise Group Inc (600080) - Total Liabilities
Based on the latest financial reports, Ginwa Enterprise Group Inc (600080) has total liabilities worth CN¥373.61 Million CNY (≈ $54.67 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Ginwa Enterprise Group Inc (600080) cash conversion ratio to assess how effectively this company generates cash.
Ginwa Enterprise Group Inc - Total Liabilities Trend (1994–2024)
This chart illustrates how Ginwa Enterprise Group Inc's total liabilities have evolved over time, based on quarterly financial data. Check asset resilience ratio of Ginwa Enterprise Group Inc to evaluate the company's liquid asset resilience ratio.
Ginwa Enterprise Group Inc Competitors by Total Liabilities
The table below lists competitors of Ginwa Enterprise Group Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Neumora Therapeutics, Inc.
NASDAQ:NMRA
|
USA | $45.67 Million |
|
Mangalore Chemicals & Fertilizers Limited
NSE:MANGCHEFER
|
India | Rs-10.65 Billion |
|
Satellogic V Inc
NASDAQ:SATL
|
USA | $127.76 Million |
|
Brasilagro Adr
NYSE:LND
|
USA | $1.66 Billion |
|
Leenos Corp
KQ:039980
|
Korea | ₩11.99 Billion |
|
Jiangsu Yitong High-tech Co Ltd
SHE:300211
|
China | CN¥169.09 Million |
|
Schweiter Technologies AG
LSE:0QR1
|
UK | £328.10 Million |
|
Aarti Drugs Limited
NSE:AARTIDRUGS
|
India | Rs11.44 Billion |
Liability Composition Analysis (1994–2024)
This chart breaks down Ginwa Enterprise Group Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Ginwa Enterprise Group Inc.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.93 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.24 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ginwa Enterprise Group Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ginwa Enterprise Group Inc (1994–2024)
The table below shows the annual total liabilities of Ginwa Enterprise Group Inc from 1994 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥412.59 Million ≈ $60.37 Million |
-12.24% |
| 2023-12-31 | CN¥470.12 Million ≈ $68.79 Million |
+61.75% |
| 2022-12-31 | CN¥290.65 Million ≈ $42.53 Million |
+35.84% |
| 2021-12-31 | CN¥213.97 Million ≈ $31.31 Million |
-9.81% |
| 2020-12-31 | CN¥237.24 Million ≈ $34.71 Million |
-10.18% |
| 2019-12-31 | CN¥264.12 Million ≈ $38.65 Million |
+29.88% |
| 2018-12-31 | CN¥203.36 Million ≈ $29.76 Million |
-32.37% |
| 2017-12-31 | CN¥300.69 Million ≈ $44.00 Million |
-18.77% |
| 2016-12-31 | CN¥370.18 Million ≈ $54.17 Million |
+74.51% |
| 2015-12-31 | CN¥212.13 Million ≈ $31.04 Million |
-13.96% |
| 2014-12-31 | CN¥246.55 Million ≈ $36.08 Million |
+32.05% |
| 2013-12-31 | CN¥186.71 Million ≈ $27.32 Million |
+15.37% |
| 2012-12-31 | CN¥161.83 Million ≈ $23.68 Million |
+7.45% |
| 2011-12-31 | CN¥150.62 Million ≈ $22.04 Million |
-78.57% |
| 2010-12-31 | CN¥702.81 Million ≈ $102.84 Million |
+2.73% |
| 2009-12-31 | CN¥684.14 Million ≈ $100.11 Million |
+1.36% |
| 2008-12-31 | CN¥674.93 Million ≈ $98.76 Million |
-26.53% |
| 2007-12-31 | CN¥918.70 Million ≈ $134.43 Million |
-24.39% |
| 2006-12-31 | CN¥1.22 Billion ≈ $177.81 Million |
-19.30% |
| 2005-12-31 | CN¥1.51 Billion ≈ $220.34 Million |
+54.61% |
| 2004-12-31 | CN¥973.91 Million ≈ $142.51 Million |
+63.91% |
| 2003-12-31 | CN¥594.19 Million ≈ $86.95 Million |
+23.17% |
| 2002-12-31 | CN¥482.42 Million ≈ $70.59 Million |
+2.40% |
| 2001-12-31 | CN¥471.11 Million ≈ $68.94 Million |
+92.73% |
| 2000-12-31 | CN¥244.44 Million ≈ $35.77 Million |
+38.95% |
| 1999-12-31 | CN¥175.92 Million ≈ $25.74 Million |
+153.35% |
| 1998-12-31 | CN¥69.44 Million ≈ $10.16 Million |
+42.97% |
| 1997-12-31 | CN¥48.57 Million ≈ $7.11 Million |
-48.71% |
| 1996-12-31 | CN¥94.69 Million ≈ $13.86 Million |
+282.87% |
| 1995-12-31 | CN¥24.73 Million ≈ $3.62 Million |
+114.82% |
| 1994-12-31 | CN¥11.51 Million ≈ $1.68 Million |
-- |
About Ginwa Enterprise Group Inc
Ginwa Enterprise (Group) Inc. researches, develops, produces, markets, and sells traditional Chinese medicines, biological drugs, and chemical drugs primarily in China. The company offers a range of orthopaedics, immunity, children, and general medicines in various dosage forms, including tablets, capsules, granules, powders, mixtures, oral solutions, syrups, and external solutions. It is also in… Read more